{"Abbreviation":"","Aliases":["Serazide","Benserazida","Ro 4-4602","Benserazidum","DL-Serine 2-(2,3,4-trihydroxybenzyl)hydrazide","Ro 44602","DL-Serine, 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide","2-amino-3-hydroxy-N'-(2,3,4-trihydroxybenzyl)propanehydrazide","DL-Seryltrihydroxybenzylhydrazine","Ro-4-4602"],"Biological Half-Life":"The half-life of benserazide is documented as 1.5 hours.","CAS":"322-35-0","ChEBI":"CHEBI:64187","ChEMBL":"CHEMBL1096979","ChemicalClasses":[],"Chirality":"racemic","Dosing Info":[],"Drug Indication":"The primary therapeutic use for which benserazide is currently indicated for is as a combination therapy with levadopa for the treatment of Parkinson's disease in adults \u003e 25 years of age, with the exception of drug-induced parkinsonism.  At certain doses, the combination product of levodopa and benserazide may also be used to treat restless legs syndrome, which is sometimes associated with Parkinson's disease.  There have also been some studies that have prompted the European Medicines Agency to confer orphan designation upon benserazide  hydrochloride as a potential therapy for beta thalassaemia. Although studies are ongoing, no evidence has been formally elucidated as of yet.","DrugClasses":[],"FullSalts":["Benserazide hydrochloride"],"HMDB ID":"HMDB0248960","HeavyAtomCount":18,"IUPACName":"2-amino-3-hydroxy-N'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide","InChI":"InChI=1S/C10H15N3O5/c11-6(4-14)10(18)13-12-3-5-1-2-7(15)9(17)8(5)16/h1-2,6,12,14-17H,3-4,11H2,(H,13,18)","InChIKey":"BNQDCRGUHNALGH-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Agents used in the treatment of Parkinson\u0026apos;s disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)","MolecularFormula":"C\u003csub\u003e10\u003c/sub\u003eH\u003csub\u003e15\u003c/sub\u003eN\u003csub\u003e3\u003c/sub\u003eO\u003csub\u003e5\u003c/sub\u003e","MolecularWeight":"257.24 g/mol","Opticalactivity":"( + / - )","Pharmacodynamics":"When used as a therapy for treating Parkinson's disease, levadopa's specific mechanism of action revolves around its metabolism into dopamine in the body. Unfortunately, the resultant increase in the levels of circulating dopamine in the blood and to various extracerebral tissues can result in a number of side effects like nausea, vomiting, or even cardiac arrhythmias that may diminish patient adherence. A decarboxylase inhibitor like benserazide is consequently an effective compound to combine with levadopa as it is incapable of crossing the blood-brain barrier itself and therefore allows levadopa to elicit its primary action in the central nervous system, but will prevent the formation of dopamine from levadopa in extracerebral tissues - thereby acting to minimize the occurrence of extracerebral side effects.","PrevSalts":["hydrochloride"],"PubChemId":2327,"Record Description":["Benserazide is a carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone. It has a role as an EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor, an antiparkinson drug and a dopaminergic agent. It is a carbohydrazide, a member of catechols, a primary amino compound and a primary alcohol. It is a conjugate base of a benserazide(1+).","When levodopa is used by itself as a therapy for treating Parkinson's disease, its ubiquitous metabolism into dopamine is responsible for a resultant increase in the levels of circulating dopamine in the blood and to various extracerebral tissues. This can result in a number of side effects like nausea, vomiting, or even cardiac arrhythmias that may diminish patient adherence. A decarboxylase inhibitor like benserazide is consequently an effective compound to combine with levadopa as it is incapable of crossing the blood-brain barrier itself but acts to prevent the formation of dopamine from levadopa in extracerebral tissues - thereby acting to minimize the occurrence of extracerebral side effects.  Levodopa/benserazide combination products are used commonly worldwide for the management of Parkinson's disease. In particular, although the specific levodopa/benserazide combination is formally approved for use in Canada and much of Europe, the FDA has approved another similar levodopa/dopa decarboxylase inhibitor combination in the form of levodopa and carbidopa.  Moreover, the European Medcines Agency has conferred an orphan designation upon benseraside since 2015 for its potential to be used as a therapy for beta thalassaemia as well.","BENSERAZIDE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications.","An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.","Benserazide is a carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone. It has a role as an EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor, an antiparkinson drug and a dopaminergic agent. It is a carbohydrazide, a member of catechols, a primary amino compound and a primary alcohol. It is a conjugate base of a benserazide(1+)."],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Benserazide","Name":"Benserazide","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q818165","Name":"Benserazide","Sub":false},{"Link":"https://www.wikidata.org/wiki/Q27285249","Name":"(+)-Benserazide","Sub":true},{"Link":"https://www.wikidata.org/wiki/Q27255228","Name":"(-)-Benserazide","Sub":true}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB12783","Name":"Benserazide","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/2327","Name":"Benserazide","Sub":false},{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/6603743","Name":"(+)-Benserazide","Sub":true},{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/40467070","Name":"(-)-Benserazide","Sub":true}]},{"Name":"ChemSpider","Urls":[{"Link":"https://www.chemspider.com/Chemical-Structure.2237.html","Name":"Benserazide","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1096979","Name":"Benserazide","Sub":false},{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1486563","Name":"(+)-Benserazide","Sub":true}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:64187","Name":"Benserazide","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=322-35-0","Name":"Benserazide","Sub":false},{"Link":"https://commonchemistry.cas.org/detail?cas_rn=26652-10-8","Name":"(+)-Benserazide","Sub":true},{"Link":"https://commonchemistry.cas.org/detail?cas_rn=212579-80-1","Name":"(-)-Benserazide","Sub":true}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0248960","Name":"Benserazide","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D03082","Name":"Benserazide","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/762OS3ZEJU","Name":"Benserazide","Sub":false},{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/O2YFO42N5P","Name":"(+)-Benserazide","Sub":true},{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/2OGJ7AR4XY","Name":"(-)-Benserazide","Sub":true}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID9022651","Name":"Benserazide","Sub":false},{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID70424956","Name":"(+)-Benserazide","Sub":true}]}],"SMILES":"C1=CC(=C(C(=C1CNNC(=O)C(CO)N)O)O)O","Salts":["hydrochloride"],"SaltsAcidCount":[1],"SaltsAmineCount":[1],"SaltsUNII":["B66E5RK36Q"],"StereoisomerRacemic":"(RS)-Benserazide","Stereoisomers":["(+)-Benserazide","(-)-Benserazide"],"StereoisomersUNII":["O2YFO42N5P","2OGJ7AR4XY"],"StoreUNII":["762OS3ZEJU"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="52.11mm" version="1.2" viewBox="0 0 146.373 52.11" width="146.373mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="53.0" stroke="none" width="147.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <g class="bond" id="mol1bnd1">
                        
                <line x1="99.345" x2="112.737" y1="41.371" y2="49.125"/>
                        
                <line x1="101.795" x2="112.739" y1="39.973" y2="46.308"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd2" x1="112.737" x2="126.024" y1="49.125" y2="41.454"/>
                  
            <g class="bond" id="mol1bnd3">
                        
                <line x1="126.024" x2="125.917" y1="41.454" y2="26.03"/>
                        
                <line x1="123.575" x2="123.488" y1="40.052" y2="27.448"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd4" x1="125.917" x2="112.765" y1="26.03" y2="18.489"/>
                  
            <g class="bond" id="mol1bnd5">
                        
                <line x1="112.765" x2="99.479" y1="18.489" y2="26.16"/>
                        
                <line x1="112.769" x2="101.905" y1="21.302" y2="27.575"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd6" x1="99.345" x2="99.479" y1="41.371" y2="26.16"/>
                  
            <line class="bond" id="mol1bnd7" x1="99.479" x2="86.314" y1="26.16" y2="18.482"/>
                  
            <line class="bond" id="mol1bnd8" x1="86.314" x2="76.239" y1="18.482" y2="24.24"/>
                  
            <line class="bond" id="mol1bnd9" x1="69.932" x2="63.068" y1="24.206" y2="20.203"/>
                  
            <line class="bond" id="mol1bnd10" x1="56.761" x2="46.686" y1="20.17" y2="25.928"/>
                  
            <g class="bond" id="mol1bnd11">
                        
                <line x1="47.908" x2="47.856" y1="25.229" y2="37.251"/>
                        
                <line x1="45.47" x2="45.417" y1="25.218" y2="37.241"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="47.856" x2="47.882000000000005" y1="37.251" y2="31.24"/>
                <line class="hi" stroke="#FF0D0D" x1="45.417" x2="45.4435" y1="37.241" y2="31.2295"/>
            </g>
                  
            <line class="bond" id="mol1bnd12" x1="46.686" x2="33.522" y1="25.928" y2="18.25"/>
                  
            <line class="bond" id="mol1bnd13" x1="33.522" x2="20.29" y1="18.25" y2="25.811"/>
                  
            <line class="bond" id="mol1bnd14" x1="20.29" x2="10.394" y1="25.811" y2="20.04"/>
                  
            <line class="bond" id="mol1bnd15" x1="33.522" x2="33.57" y1="18.25" y2="7.188"/>
                  
            <line class="bond" id="mol1bnd16" x1="112.765" x2="112.748" y1="18.489" y2="7.17"/>
                  
            <line class="bond" id="mol1bnd17" x1="125.917" x2="135.805" y1="26.03" y2="20.255"/>
                  
            <line class="bond" id="mol1bnd18" x1="126.024" x2="135.958" y1="41.454" y2="47.144"/>
                  
            <g class="atom" id="mol1atm8">
                        
                <path d="M75.023 28.493h-.72l-2.62 -4.066h-.029q.012 .239 .029 .596q.024 .357 .024 .732v2.738h-.565v-4.899h.714l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.023 -.477q-.006 -.261 -.006 -.482v-2.768h.577v4.899z" fill="#3050F8" stroke="none"/>
                        
                <path d="M74.886 33.955h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619v4.9z" fill="#3050F8" stroke="none"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm9">
                        
                <path d="M61.859 20.815h-.721l-2.619 -4.066h-.03q.012 .239 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.714l2.608 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" fill="#3050F8" stroke="none"/>
                        
                <path d="M61.722 15.354h-.62v-2.286h-2.512v2.286h-.613v-4.899h.613v2.072h2.512v-2.072h.62v4.899z" fill="#3050F8" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M48.878 41.164q.0 .757 -.256 1.328q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.751 .244 -1.31q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM45.015 41.164q-.0 .923 .387 1.459q.393 .53 1.22 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.459q.0 -.928 -.387 -1.452q-.381 -.524 -1.208 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.452z" id="mol1atm11" stroke="none"/>
                  
            <g class="atom" id="mol1atm14">
                        
                <path d="M9.385 18.13q-.0 .756 -.256 1.328q-.256 .566 -.756 .881q-.5 .316 -1.245 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q.0 -.751 .244 -1.31q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.733 .0 1.233 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM5.521 18.13q.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.928 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .524 -.393 1.452z" stroke="none"/>
                        
                <path d="M4.305 20.583h-.62v-2.286h-2.512v2.286h-.613v-4.899h.613v2.071h2.512v-2.071h.62v4.899z" stroke="none"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm15">
                        
                <path d="M35.529 5.459h-.72l-2.619 -4.066h-.03q.012 .239 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.714l2.608 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" fill="#3050F8" stroke="none"/>
                        
                <path d="M39.836 5.459h-.62v-2.286h-2.512v2.286h-.613v-4.899h.613v2.072h2.512v-2.072h.62v4.899z" fill="#3050F8" stroke="none"/>
                        
                <path d="M42.34 6.949h-1.943v-.3l.772 -.779q.221 -.221 .371 -.393q.154 -.175 .232 -.339q.079 -.168 .079 -.364q.0 -.243 -.146 -.368q-.143 -.129 -.372 -.129q-.214 .0 -.379 .075q-.16 .075 -.328 .207l-.193 -.243q.171 -.146 .393 -.246q.225 -.1 .507 -.1q.411 -.0 .65 .207q.239 .207 .239 .575q.0 .229 -.096 .432q-.093 .2 -.264 .397q-.168 .196 -.393 .418l-.615 .603v.018h1.486v.329z" fill="#3050F8" stroke="none"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm16">
                        
                <path d="M115.001 3.246q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.245 -.572 -.245 -1.334q.0 -.75 .245 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM111.137 3.246q.0 .923 .387 1.459q.393 .53 1.221 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.459q.0 -.929 -.387 -1.452q-.381 -.524 -1.208 -.524q-.834 -.0 -1.227 .524q-.393 .523 -.393 1.452z" stroke="none"/>
                        
                <path d="M119.307 5.699h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619v4.9z" stroke="none"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm17">
                        
                <path d="M141.337 18.341q-.0 .756 -.256 1.328q-.256 .565 -.757 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.501 .309 .757 .875q.256 .565 .256 1.327zM137.473 18.341q-.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" stroke="none"/>
                        
                <path d="M145.643 20.794h-.619v-2.286h-2.513v2.286h-.613v-4.9h.613v2.072h2.513v-2.072h.619v4.9z" stroke="none"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm18">
                        
                <path d="M141.507 49.025q.0 .757 -.256 1.328q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.751 .244 -1.31q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM137.644 49.025q-.0 .923 .387 1.459q.393 .53 1.22 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.459q.0 -.928 -.387 -1.452q-.381 -.524 -1.208 -.524q-.834 .0 -1.226 .524q-.393 .524 -.393 1.452z" stroke="none"/>
                        
                <path d="M145.813 51.478h-.619v-2.286h-2.512v2.286h-.613v-4.899h.613v2.071h2.512v-2.071h.619v4.899z" stroke="none"/>
                      
            </g>
                
            <line class="hi" id="mol1bnd8" stroke="#3050F8" x1="76.239" x2="81.2765" y1="24.24" y2="21.360999999999997"/>
            <line class="hi" id="mol1bnd9" stroke="#3050F8" x1="69.932" x2="66.5" y1="24.206" y2="22.2045"/>
            <line class="hi" id="mol1bnd9" stroke="#3050F8" x1="63.068" x2="66.5" y1="20.203" y2="22.2045"/>
            <line class="hi" id="mol1bnd9" stroke="#3050F8" x1="63.068" x2="66.5" y1="20.203" y2="22.2045"/>
            <line class="hi" id="mol1bnd10" stroke="#3050F8" x1="56.761" x2="51.7235" y1="20.17" y2="23.049"/>
            <line class="hi" id="mol1bnd10" stroke="#3050F8" x1="56.761" x2="51.7235" y1="20.17" y2="23.049"/>
            <line class="hi" id="mol1bnd14" stroke="#FF0D0D" x1="10.394" x2="15.341999999999999" y1="20.04" y2="22.9255"/>
            <line class="hi" id="mol1bnd14" stroke="#FF0D0D" x1="10.394" x2="15.341999999999999" y1="20.04" y2="22.9255"/>
            <line class="hi" id="mol1bnd15" stroke="#3050F8" x1="33.57" x2="33.546" y1="7.187999999999999" y2="12.719"/>
            <line class="hi" id="mol1bnd15" stroke="#3050F8" x1="33.57" x2="33.546" y1="7.187999999999999" y2="12.719"/>
            <line class="hi" id="mol1bnd16" stroke="#FF0D0D" x1="112.748" x2="112.7565" y1="7.17" y2="12.8295"/>
            <line class="hi" id="mol1bnd16" stroke="#FF0D0D" x1="112.748" x2="112.7565" y1="7.17" y2="12.8295"/>
            <line class="hi" id="mol1bnd17" stroke="#FF0D0D" x1="135.805" x2="130.861" y1="20.255" y2="23.1425"/>
            <line class="hi" id="mol1bnd18" stroke="#FF0D0D" x1="135.958" x2="130.99099999999999" y1="47.144" y2="44.299"/>
        </g>
          
    </g>
    
</svg>
","Title":"Benserazide","UNII":"762OS3ZEJU","Wikidata":"Q818165","XLogP":-1.3}